ADAM17 and metastatic malignant neoplasm in the lymph nodes: ADAM17 expression is associated with poor survival (HR = 2.04, 95% CI = 1.66–2.52, p < 0.001), lymph node metastasis (OR = 5.47, 95% CI = 3.98–7.51, p < 0.001) and distant metastasis (OR = 3.50, 95% CI = 1.79–6.87, p < 0.001) in many types of tumors [177].